M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Syncona to acquire Freeline Therapeutics Holdings plc
Announced Nov 22, 2023 · Closed Feb 20, 2024
Deal value$28MEV $28M
Premium51.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$6.50 per share
Transaction
- Acquirer
- Syncona
- Target
- Freeline Therapeutics Holdings plc (FRLN)
- Buyer type
- Strategic
- Offer price per share
- $6.50
- Enterprise value
- $28M
- Status
- Closed Feb 20, 2024
Deal protections
Not yet read from the merger agreement.
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 95 in the prior 24 months
- Premium
- 51.0% vs. 52.0% sector median
- EV / Adj. EBITDA
- Sector median 17.1x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedNov 22, 2023
- ClosedFeb 20, 2024